Cyclin D as a therapeutic target in cancer
The DOI matches its Crossref record; 191 of the 191 references it cites were found in a registry or an index.
Abstract
Cyclin D1, and to a lesser extent the other D-type cyclins, is frequently deregulated in cancer and is a biomarker of cancer phenotype and disease progression. The ability of these cyclins to activate the cyclin-dependent kinases (CDKs) CDK4 and CDK6 is the most extensively documented mechanism for their oncogenic actions and provides an attractive therapeutic target. Is this an effective means of targeting the cyclin D oncogenes, and how might the patient subgroups that are most likely to benefit be identified?
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Failure to modify cyclin D1 on T286 leads to aberrant nuclear accumulation of the protein, premature S phase entry, and enhanced cellular proliferation that drives tumorigenesis (17).”
From A genome-wide screen reveals that Dyrk1A kinase promotes nucleotide excision repair by preventing aberrant overexpression of cyclin D1 and p21 (2023) · cites this paper as [17]
In the citing paper
“Possibly, CCND1 amplification and CDKN2A loss may contribute to determining response to letrozole alone”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [68]
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · cited 1×
“The deregulation of cyclin expression or CDK activation can directly lead to some of the hallmarks of cance”
BackgroundComprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
CDK inhibitors: positive and negative regulators of G1-phase progression
Sherr, C. J., & Roberts, J. M. (1999) · Genes & Development · doi:10.1101/gad.13.12.1501 · Cited by 6,115 · cited 1×
“A second well-described non-catalytic role of cyclin D is the sequestration of p21 and p27 by cyclin D–CDK4/CDK6, leading to the indirect activation of CDK2 (REF”
BackgroundIn Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661 · cited 1×
“It may also be possible to identify low-molecular-mass inhibitors of cyclin–CDK substrate interactions using high-throughput screens that are similar to those used for the discovery and preclinical testing of inhibitors of MDM2–p53 binding (nutlins”
MethodThe landscape of somatic copy-number alteration across human cancers
Beroukhim, R., Mermel, C. H., Porter, D., Wei, G., Raychaudhuri, S., Donovan, J., Barretina, J., Boehm, J. S., Dobson, J., Urashima, M., et al. (2010) · Nature · doi:10.1038/nature08822 · Cited by 4,017
Cell cycle, CDKs and cancer: a changing paradigm
Malumbres, M., & Barbacid, M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2602 · Cited by 3,957 · cited 1×
“by causing proliferation that is independent of normal extracellular cues, or by over-riding checkpoints that ensure genomic integrity and stabilit”
BackgroundFinn, R. S., Dering, J., Conklin, D., Kalous, O., Cohen, D. J., Desai, A. J., Ginther, C., Atefi, M., Chen, I., Fowst, C., et al. (2009) · Breast Cancer Research · doi:10.1186/bcr2419 · Cited by 1,398
Tyrosine Kinases as Targets for Cancer Therapy
Krause, D. S., & Van Etten, R. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmra044389 · Cited by 1,387 · cited 1×
“Given the increasingly routine clinical use of specific kinase inhibitor”
BackgroundmTOR and cancer: insights into a complex relationship
Sabatini, D. M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1974 · Cited by 1,322 · cited 1×
“In Phase II clinical trials mTOR inhibitors were particularly effective in MCL, which is characterized by almost universal overexpression of cyclin D1, although this may not be accompanied by a reduction in cyclin D1 expression (reviewed in REF”
BackgroundBiological determinants of endocrine resistance in breast cancer
Musgrove, E. A., & Sutherland, R. L. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2713 · Cited by 1,252
Self-citation
Cited by
Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers
Lovén, J., Hoke, H. A., Lin, C. Y., Lau, A., Orlando, D. A., Vakoc, C. R., Bradner, J. E., Lee, T. I., & Young, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.03.036 · Cited by 2,961
“Cyclin D2 (CCND2) is deregulated in many human cancers, including MM (Bergsagel et al., 2005; Musgrove et al., 2011).”
BackgroundPalbociclib in hormone-receptor-positive advanced breast cancer
Turner, N. C., Ro, J., André, F., Loi, S., Verma, S., Iwata, H., Harbeck, N., Loibl, S., Huang Bartlett, C., Zhang, K., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1505270 · Cited by 1,590
Emerging landscape of oncogenic signatures across human cancers
Ciriello, G., Miller, M. L., Aksoy, B. A., Senbabaoglu, Y., Schultz, N., & Sander, C. (2013) · Nature Genetics · doi:10.1038/ng.2762 · Cited by 1,378
Treating cancer with selective CDK4/6 inhibitors
O'Leary, B., Finn, R. S., & Turner, N. C. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.26 · Cited by 1,137
Targeting CDK4 and CDK6: From Discovery to Therapy
Sherr, C. J., Beach, D., & Shapiro, G. I. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0894 · Cited by 936
“Although several lines of evidence argue for CDK4/6-independent roles of D-type cyclins as transcriptional cofactors for HRs (68) and”
Sustained proliferation in cancer: Mechanisms and novel therapeutic targets
Feitelson, M. A., Arzumanyan, A., Kulathinal, R. J., Blain, S. W., Holcombe, R. F., Mahajna, J., Marino, M., Martinez-Chantar, M. L., Nawroth, R., Sanchez-Garcia, I., et al. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.02.006 · Cited by 778
Herrera-Abreu, M. T., Palafox, M., Asghar, U., Rivas, M. A., Cutts, R. J., Garcia-Murillas, I., Pearson, A., Guzman, M., Rodriguez, O., Grueso, J., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-0728 · Cited by 762
Dickler, M. N., Tolaney, S. M., Rugo, H. S., Cortés, J., Diéras, V., Patt, D., Wildiers, H., Hudis, C. A., O'Shaughnessy, J., Zamora, E., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0754 · Cited by 676
“CDK4 and CDK6, together with D-type cyclins, phosphorylate the Retinoblastoma (Rb) tumor-suppressor protein, leading to release of Rb-bound E2F, which enables progression from the G1 to S phase of the cell cycle (15, 16).”
BackgroundCyclin D1, cancer progression, and opportunities in cancer treatment
Qie, S., & Diehl, J. A. (2016) · Journal of Molecular Medicine · doi:10.1007/s00109-016-1475-3 · Cited by 657
“Clinicopathological studies showed that cyclin D1 overexpression correlates with tumor metastasis and poor prognosis in a series of human cancers [7, 123, 134].”
BackgroundInfluentialTargeting CDK4 and CDK6 in cancer
Goel, S., Bergholz, J. S., & Zhao, J. J. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00456-3 · Cited by 531
Non-canonical functions of cell cycle cyclins and cyclin-dependent kinases
Hydbring, P., Malumbres, M., & Sicinski, P. (2016) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2016.27 · Cited by 528
Montalto, F. I., & De Amicis, F. (2020) · Cells · doi:10.3390/cells9122648 · Cited by 496
“Cyclin D1 protein consists of an RB protein binding portion, a domain for CDK binding or CDK inhibitor, a LxxLL motif recruiting coactivators, PEST site for Cyclin D1 degradation and a residual threonine, which controls nuclear export and protein stability [26].”
BackgroundTargeting CDK4/6 in patients with cancer
Hamilton, E., & Infante, J. R. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.03.002 · Cited by 481
“Amplification of CCND1 is also frequently observed in head and neck cancer (26–39% of cases), non-small cell lung cancer (NSCLC; 5–30%), endometrial carcinoma (26%), and pancreatic cancer (25%) [11].”
BackgroundLuminal B Breast Cancer: Molecular Characterization, Clinical Management, and Future Perspectives
Ades, F., Zardavas, D., Bozovic-Spasojevic, I., Pugliano, L., Fumagalli, D., de Azambuja, E., Viale, G., Sotiriou, C., & Piccart, M. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.1870 · Cited by 435
Challenges and Opportunities in Cancer Drug Resistance
Ward, R. A., Fawell, S., Floc’h, N., Flemington, V., McKerrecher, D., & Smith, P. D. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00383 · Cited by 445
Cyclin-dependent protein serine/threonine kinase inhibitors as anticancer drugs
Roskoski, R. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2018.11.035 · Cited by 393
Molecular pathways: targeting the cyclin D-CDK4/6 axis for cancer treatment
VanArsdale, T., Boshoff, C., Arndt, K. T., & Abraham, R. T. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0816 · Cited by 396
Dual CDK4/CDK6 Inhibition Induces Cell-Cycle Arrest and Senescence in Neuroblastoma
Rader, J., Russell, M. R., Hart, L. S., Nakazawa, M. S., Belcastro, L. T., Martinez, D., Li, Y., Carpenter, E. L., Attiyeh, E. F., Diskin, S. J., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1675 · Cited by 394
“Over the last decade, first-generationCDK inhibitors have been evaluated in clinical trials for the treatment of adult malignancies, and a number of second-generation CDK inhibitors are currently undergoing phase I and phase II testing (7, 36).”
BackgroundTargeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers
Finn, R. S., Aleshin, A., & Slamon, D. J. (2016) · Breast Cancer Research · doi:10.1186/s13058-015-0661-5 · Cited by 368
Discovery of multi-dimensional modules by integrative analysis of cancer genomic data
Zhang, S., Liu, C.-C., Li, W., Shen, H., Laird, P. W., & Zhou, X. J. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks725 · Cited by 374
“Mutations, amplification or overexpression of CCND1, which alter the cell cycle progression, are observed frequently in a variety of tumors (41,42).”
BackgroundThe molecular pathogenesis of head and neck squamous cell carcinoma
Rothenberg, S. M., & Ellisen, L. W. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59889 · Cited by 363
“34).”
Cyclin-dependent protein kinases and cell cycle regulation in biology and disease
Pellarin, I., Dall’Acqua, A., Favero, A., Segatto, I., Rossi, V., Crestan, N., Karimbayli, J., Belletti, B., & Baldassarre, G. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02080-z · Cited by 304
Targeting Cyclin-Dependent Kinases in Human Cancers: From Small Molecules to Peptide Inhibitors
Peyressatre, M., Prével, C., Pellerano, M., & Morris, M. (2015) · Cancers · doi:10.3390/cancers7010179 · Cited by 344
“CDK4 hyperactivity is further often associated with Cyclin D overexpression, genetic amplification, polymorphism, translocation or alternative splicing [134,238].”
BackgroundZhang, E.-B., Kong, R., Yin, D.-D., You, L.-H., Sun, M., Han, L., Xu, T.-P., Xia, R., Yang, J.-S., De, W., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.1902 · Cited by 351
“To detect the impact of ANRIL on the activities of mTOR[33] and CDK6[34], we performed western blot assays to measure p-mTOR, phospho-S6 Kinase1, phospho-S6, p15, p16 and cyclinD1.”
MethodThe Requirement for Cyclin D Function in Tumor Maintenance
Choi, Y. J., Li, X., Hydbring, P., Sanda, T., Stefano, J., Christie, A. L., Signoretti, S., Look, A. T., Kung, A. L., von Boehmer, H., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.09.015 · Cited by 342
“Moreover, in many human cancers overexpression of D-type cyclins takes place in the absence of any detectable genomic alterations (Deshpande et al., 2005; Fu et al., 2004; Musgrove et al. 2011).”
BackgroundInfluentialLiang, J., & Shang, Y. (2013) · Annual Review of Physiology · doi:10.1146/annurev-physiol-030212-183708 · Cited by 314
“The mitogenic effects of estrogen are particularly clear at the G1-to-S transition, during which the key effectors of estrogen action are c-Myc and cyclin D1 (49, 50).”
BackgroundLandscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma
Zhao, S., Choi, M., Overton, J. D., Bellone, S., Roque, D. M., Cocco, E., Guzzo, F., English, D. P., Varughese, J., Gasparrini, S., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1222577110 · Cited by 320
“One known function of TAF1 is promotion of cyclin D expression; overexpression of cyclin D is itself known to promote cell cycle progression and proliferation and is frequently amplified in cancers (28).”
BackgroundCDK4/6 inhibition in breast cancer: current practice and future directions
Pernas, S., Tolaney, S. M., Winer, E. P., & Goel, S. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835918786451 · Cited by 316
A Kinase-Independent Function of CDK6 Links the Cell Cycle to Tumor Angiogenesis
Kollmann, K., Heller, G., Schneckenleithner, C., Warsch, W., Scheicher, R., Ott, R. G., Schäfer, M., Fajmann, S., Schlederer, M., Schiefer, A.-I., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.07.012 · Cited by 313
“Recent studies have shown that D-type cyclins have transcriptional activity (Bienvenu et al., 2010; Despouy et al., 2003; Musgrove et al., 2011).”
BackgroundSun, C., Li, S., Zhang, F., Xi, Y., Wang, L., Bi, Y., & Li, D. (2016) · Oncotarget · doi:10.18632/oncotarget.10108 · Cited by 312
“We next examined the influence of NEAT1 on the expression of cyclin D1, a well-established human oncogene [44], which is over-expressed in lung cancer, breast cancer and pancreatic cancer [44–47], and over-expression of cyclin D1 is involved in malignant transformation in lung tissue [48].”
BackgroundFricker, L. D. (2020) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010919-023603 · Cited by 309
The JAK2/STAT3/CCND2 Axis promotes colorectal Cancer stem cell persistence and radioresistance
Park, S.-Y., Lee, C.-J., Choi, J.-H., Kim, J.-H., Kim, J.-W., Kim, J.-Y., & Nam, J.-S. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1405-7 · Cited by 292
Signaling through cyclin D-dependent kinases
Choi, Y. J., & Anders, L. (2014) · Oncogene · doi:10.1038/onc.2013.137 · Cited by 278
The Function of V-ATPases in Cancer
Stransky, L., Cotter, K., & Forgac, M. (2016) · Physiological Reviews · doi:10.1152/physrev.00035.2015 · Cited by 276
The double dealing of cyclin D1
Tchakarska, G., & Sola, B. (2020) · Cell Cycle · doi:10.1080/15384101.2019.1706903 · Cited by 278
“[45] Musgrove EA, Caldon CE, Barraclough J, et al.”
BackgroundInfluentialThe Eukaryotic Linear Motif resource: 2022 release
Kumar, M., Michael, S., Alvarado-Valverde, J., Mészáros, B., Sámano-Sánchez, H., Zeke, A., Dobson, L., Lazar, T., Örd, M., Nagpal, A., et al. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkab975 · Cited by 245
“Mutation of these degron sequences and the flanking regions regulating nuclear export can contribute to cyclin D overexpression observed in human tumours (36).”
Chang, J., Tan, W., Ling, Z., Xi, R., Shao, M., Chen, M., Luo, Y., Zhao, Y., Liu, Y., Huang, X., et al. (2017) · Nature Communications · doi:10.1038/ncomms15290 · Cited by 248
Tripathy, D., Bardia, A., & Sellers, W. R. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3157 · Cited by 247
“Breast tumors frequently harbor aberrations of the cyclin D–CDK4/6–p16–Rb pathway (34-36) (Supplementary Table 1), and this pathway is also implicated in resistance to endocrine therapy (3).”
Gong, X., Litchfield, L. M., Webster, Y., Chio, L.-C., Wong, S. S., Stewart, T. R., Dowless, M., Dempsey, J., Zeng, Y., Torres, R., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.11.006 · Cited by 236
“…Cell 32, 761–776, December 11, 2017 functions of D-type cyclins do not require kinase activity (Jirawatnotai et al., 2011; Knudsen et al., 1999; Musgrove et al., 2011; Neuman et al., 1997), and copy number changes affecting CCND1, CDK4, or CDKN2A typically also affect neighboring oncogenes or…”
InfluentialCyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs
Roskoski, R. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.03.012 · Cited by 237
“Cyclin D1 amplification occurs in 15–40% of all cancers [23] including breast, lung, and oral carcinomas and melanomas [24].”
Cyclin dependent kinase (CDK) inhibitors as anticancer drugs
Sánchez-Martínez, C., Gelbert, L. M., Lallena, M. J., & de Dios, A. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.05.100 · Cited by 230
Mild Magnetic Hyperthermia-Activated Innate Immunity for Liver Cancer Therapy
Pan, J., Xu, Y., Wu, Q., Hu, P., & Shi, J. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.1c02537 · Cited by 224
Cyclins and Cell Cycle Control in Cancer and Disease
Casimiro, M. C., Crosariol, M., Loro, E., Li, Z., & Pestell, R. G. (2012) · Genes & Cancer · doi:10.1177/1947601913479022 · Cited by 216
“Cyclin D1 plays an important role in cell cycle progression through the association with CDK4 and CDK6, which phosphorylate and inactivate the retinoblastoma protein pRb, leading to the expression of a subset of proliferation-associated E2F target genes.(2,3) In addition to this canonical pRB-dependent effect in cell…”
BackgroundSack, L. M., Davoli, T., Li, M. Z., Li, Y., Xu, Q., Naxerova, K., Wooten, E. C., Bernardi, R. J., Martin, T. D., Chen, T., et al. (2018) · Cell · doi:10.1016/j.cell.2018.02.037 · Cited by 229
“Because the E2F1 transcription factor is inhibited by RB1 and the ‘‘E2F-mediated regulation of DNA replication’’ pathway was enriched after KRTAP expression (Table S4), we examined E2F1 levels and found that expression of 2 independent and potent KRTAPs (10-6 and 4-5) led to a 2-fold increase of E2F1 RNA and protein (…”
InfluentialPrognostic biomarkers in oral squamous cell carcinoma: A systematic review
Rivera, C., Oliveira, A. K., Costa, R. A. P., De Rossi, T., & Paes Leme, A. F. (2017) · Oral Oncology · doi:10.1016/j.oraloncology.2017.07.003 · Cited by 208
Waddell, I. S., & Orfila, C. (2023) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2022.2061909 · Cited by 211
“As CDK4 and CDK6 are known to encourage the proliferation and growth of cells through the advancement of the cell cycle, their inhibition is important in preventing the growth and development of cancerous cells and stopping their progression to tumors (Musgrove et al. 2011).”
BackgroundCDK4: A Key Player in the Cell Cycle, Development, and Cancer
Baker, S. J., & Reddy, E. P. (2012) · Genes & Cancer · doi:10.1177/1947601913478972 · Cited by 194
CDK 4/6 Inhibitors as Single Agent in Advanced Solid Tumors
Schettini, F., De Santo, I., Rea, C. G., De Placido, P., Formisano, L., Giuliano, M., Arpino, G., De Laurentiis, M., Puglisi, F., De Placido, S., et al. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00608 · Cited by 201
“CCND interact with several CDK, including CDK 4/6, forming functional complexes that phosphorylate and inactivate retinoblastoma protein (pRb) (1).”
BackgroundInfluentialPreclinical characterization of abemaciclib in hormone receptor positive breast cancer
Torres-Guzmán, R., Calsina, B., Hermoso, A., Baquero, C., Alvarez, B., Amat, J., McNulty, A. M., Gong, X., Boehnke, K., Du, J., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17778 · Cited by 196
“CDK4 and Cyclin D1 may be especially relevant for breast cancer, since evidence suggests that both are important oncogenic drivers for this disease [4, 9, 10, 12, 26].”
BackgroundSal-like protein 4 (SALL4), a stem cell biomarker in liver cancers
Oikawa, T., Kamiya, A., Zeniya, M., Chikada, H., Hyuck, A. D., Yamazaki, Y., Wauthier, E., Tajiri, H., Miller, L. D., Wang, X. W., et al. (2013) · Hepatology · doi:10.1002/hep.26159 · Cited by 195
“One of the main regulators of G1-S phase transition in the cell cycle, Cyclin D1, has been shown to have capabilities of carcinogenesis and progression in cancer through controlling cell proliferation.(44) Moreover, the strong relationship of tumorigenesis and self-renewal by Ras-Cyclin D2 activation has been elucidat…”
BackgroundEstrogen receptor signaling as a target for novel breast cancer therapeutics
Renoir, J.-M., Marsaud, V., & Lazennec, G. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.10.018 · Cited by 193
“Among these genes, some are activated like those involved in cell cycle progression (such as c-myc, cyclins D, A and E) and the expression of others, such as the gene for the cyclin-dependent kinase (CDK) inhibitor p21, is decreased [14].”
BackgroundCombined CDK4/6 and PI3Kα Inhibition Is Synergistic and Immunogenic in Triple-Negative Breast Cancer
Teo, Z. L., Versaci, S., Dushyanthen, S., Caramia, F., Savas, P., Mintoff, C. P., Zethoven, M., Virassamy, B., Luen, S. J., McArthur, G. A., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-2210 · Cited by 196
McCartney, A., Migliaccio, I., Bonechi, M., Biagioni, C., Romagnoli, D., De Luca, F., Galardi, F., Risi, E., De Santo, I., Benelli, M., et al. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00666 · Cited by 180
“Dysregulation of the CDK4/6 pathway, occasioning unchecked cell-cycle progression and proliferation, has been implicated in breast cancer (BC) via various mechanisms, including amplification of cyclin D1 (2), gain of CDK4, low expression of p18/high expression of RB1 (3) and inactivation of p16, the tumor suppressor p…”
BackgroundLncRNA DILA1 inhibits Cyclin D1 degradation and contributes to tamoxifen resistance in breast cancer
Shi, Q., Li, Y., Li, S., Jin, L., Lai, H., Wu, Y., Cai, Z., Zhu, M., Li, Q., Li, Y., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19349-w · Cited by 188
Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO), Jia, W.-H., Colon Cancer Family Registry (CCFR), Zhang, B., Matsuo, K., Shin, A., Xiang, Y.-B., Jee, S. H., Kim, D.-H., Ren, Z., et al. (2013) · Nature Genetics · doi:10.1038/ng.2505 · Cited by 183
Lücking, U., Jautelat, R., Krüger, M., Brumby, T., Lienau, P., Schäfer, M., Briem, H., Schulze, J., Hillisch, A., Reichel, A., et al. (2013) · ChemMedChem · doi:10.1002/cmdc.201300096 · Cited by 182
Martínez-Alonso, D., & Malumbres, M. (2020) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2020.03.009 · Cited by 179
Emerging targeted agents in metastatic breast cancer
Zardavas, D., Baselga, J., & Piccart, M. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.29 · Cited by 178
Cell Death in Chondrocytes, Osteoblasts, and Osteocytes
Komori, T. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17122045 · Cited by 176
“This leads to the transcriptional activation of E2f-responsive genes that are essential for DNA synthesis, including cyclins E and A [16].”
BackgroundTargeting CDK6 in cancer: State of the art and new insights
Tadesse, S., Yu, M., Kumarasiri, M., Le, B. T., & Wang, S. (2015) · Cell Cycle · doi:10.1080/15384101.2015.1084445 · Cited by 163
Kowshik, J., Baba, A. B., Giri, H., Deepak Reddy, G., Dixit, M., & Nagini, S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0109114 · Cited by 158
“Downregulation of the cell cycle regulatory proteins cyclin D1 and PCNA, biomarkers of the malignant phenotype and tumor progression with increased expression of p21 the most potent CDK inhibitor, underscore the antiproliferative effects of astaxanthin.”
BackgroundInfluentialRB1 dual role in proliferation and apoptosis: Cell fate control and implications for cancer therapy
Indovina, P., Pentimalli, F., Casini, N., Vocca, I., & Giordano, A. (2015) · Oncotarget · doi:10.18632/oncotarget.4286 · Cited by 163
“Nevertheless, a potent and highly selective inhibitor of CDK4 and CDK6, called Palbociclib (PD-0332991), recently proved to be dependent on the presence of RB1 for its antiproliferative effect in several cancer cell lines and xenograft models [133] and a Phase I trial of PD-0332991 utilized RB1-deficiency as an exclus…”
Kemps, P. G., Picarsic, J., Durham, B. H., Hélias-Rodzewicz, Z., Hiemcke-Jiwa, L., van den Bos, C., van de Wetering, M. D., van Noesel, C. J. M., van Laar, J. A. M., Verdijk, R. M., et al. (2022) · Blood · doi:10.1182/blood.2021013338 · Cited by 163
Schödel, J., Bardella, C., Sciesielski, L. K., Brown, J. M., Pugh, C. W., Buckle, V., Tomlinson, I. P., Ratcliffe, P. J., & Mole, D. R. (2012) · Nature Genetics · doi:10.1038/ng.2204 · Cited by 158
Malorni, L., Piazza, S., Ciani, Y., Guarducci, C., Bonechi, M., Biagioni, C., Hart, C. D., Verardo, R., Leo, A. D., & Migliaccio, I. (2016) · Oncotarget · doi:10.18632/oncotarget.12010 · Cited by 162
“The retinoblastoma susceptibility gene product (Rb) is a key regulator of cell cycle progression [2].”
BackgroundOvercoming CDK4/6 inhibitor resistance in ER-positive breast cancer
Portman, N., Alexandrou, S., Carson, E., Wang, S., Lim, E., & Caldon, C. E. (2019) · Endocrine-Related Cancer · doi:10.1530/erc-18-0317 · Cited by 163
Self-citationSiemeister, G., Lücking, U., Wengner, A. M., Lienau, P., Steinke, W., Schatz, C. A., Mumberg, D., & Ziegelbauer, K. B. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0286 · Cited by 176
“because of insufficient potency, pharmacokinetic and physicochemical properties, off-target toxicities, and suboptimal dosing schedules (14).”
Peptide-based nanoprobes for molecular imaging and disease diagnostics
Zhang, P., Cui, Y., Anderson, C. F., Zhang, C., Li, Y., Wang, R., & Cui, H. (2018) · Chemical Society Reviews · doi:10.1039/c7cs00793k · Cited by 160
Targeted therapy for breast cancer: An overview of drug classes and outcomes
Jacobs, A. T., Castaneda-Cruz, D. M., Rose, M. M., & Connelly, L. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115209 · Cited by 173
Modification of the DNA Damage Response by Therapeutic CDK4/6 Inhibition
Dean, J. L., McClendon, A. K., & Knudsen, E. S. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.365494 · Cited by 155
Identification of susceptibility loci for colorectal cancer in a genome-wide meta-analysis
Whiffin, N., Hosking, F. J., Farrington, S. M., Palles, C., Dobbins, S. E., Zgaga, L., Lloyd, A., Kinnersley, B., Gorman, M., Tenesa, A., et al. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu177 · Cited by 170
Derakhshan, A., Chen, Z., & Waes, C. V. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2172 · Cited by 163
“In addition, the 11q13 region harbors another oncogene (CCND1), which promotes cellcycle progression and tumor proliferation (57, 58).”
BackgroundCaldon, C. E., Sergio, C. M., Kang, J., Muthukaruppan, A., Boersma, M. N., Stone, A., Barraclough, J., Lee, C. S., Black, M. A., Miller, L. D., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0963 · Cited by 151
“Consequently, endocrine-resistant breast cancer is one disease subtype in which cyclin-dependent kinase (CDK) inhibitors with specificity for the cyclin D1-associated kinases CDK4 and CDK6 may offer significant clinical benefit (7).”
BackgroundInfluentialSelf-citationThe prognostic significance and value of cyclin D1, CDK4 and p16 in human breast cancer
Peurala, E., Koivunen, P., Haapasaari, K., Bloigu, R., & Jukkola‐Vuorinen, A. (2013) · Breast Cancer Research · doi:10.1186/bcr3376 · Cited by 150
“Cyclin D1 is a product of the CCND1 gene [12], which is today considered a well-established human oncogene [5].”
BackgroundInfluentialHarnessing Allostery: A Novel Approach to Drug Discovery
Lu, S., Li, S., & Zhang, J. (2014) · Medicinal Research Reviews · doi:10.1002/med.21317 · Cited by 141
Zhou, W., & Slingerland, J. M. (2013) · Nature reviews. Cancer · doi:10.1038/nrc3622 · Cited by 161
Benítez, J. A., Ma, J., D’Antonio, M., Boyer, A. D., Camargo, M. F., Zanca, C., Kelly, S., Khodadadi‐Jamayran, A., Jameson, N. M., Andersen, M., et al. (2017) · Nature Communications · doi:10.1038/ncomms15223 · Cited by 160
Miller, T., & Hosford, S. (2014) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s52762 · Cited by 141
Guarducci, C., Bonechi, M., Benelli, M., Biagioni, C., Boccalini, G., Romagnoli, D., Verardo, R., Schiff, R., Osborne, C. K., Angelis, C. D., et al. (2018) · npj Breast Cancer · doi:10.1038/s41523-018-0092-4 · Cited by 153
Targeting Cyclin-Dependent Kinases and Cell Cycle Progression in Human Cancers
Santo, L., Siu, K. T., & Raje, N. S. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.09.024 · Cited by 142
Xia, B., Yang, S., Liu, T., & Lou, G. (2015) · Molecular Cancer · doi:10.1186/s12943-015-0322-4 · Cited by 143
“Hundreds of potential targets were found, but we selected transcription factor 4 (TCF4), Cyclin D1, Cyclin D2, Cyclin D3 and Cyclin dependent kinase 6 (CDK6) for further analysis since these genes have previously been reported to affect EOC cell proliferation [28-31] (Figure 4A).”
BackgroundInfluentialDiscovery of PF-06873600, a CDK2/4/6 Inhibitor for the Treatment of Cancer
Freeman‐Cook, K. D., Hoffman, R. L., Behenna, D. C., Boras, B. W., Carelli, J. D., Diehl, W. C., Ferre, R. A., He, Y.-A., Hui, A., Huang, B., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00159 · Cited by 136
Protein kinase C signaling and cell cycle regulation
Black, A. R., & Black, J. D. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00423 · Cited by 125
“Entry of quiescent cells into the cell cycle and transit through early G1 is regulated by D-type cyclins, which complex with cdk4 and cdk6 (Musgrove et al., 2011).”
BackgroundLoss of FXR Protects against Diet-Induced Obesity and Accelerates Liver Carcinogenesis in ob/ob Mice
Zhang, Y., Ge, X., Heemstra, L. A., Chen, W.-D., Xu, J., Smith, J. L., Ma, H., Kasim, N., Edwards, P. A., & Novak, C. M. (2012) · Molecular Endocrinology · doi:10.1210/me.2011-1157 · Cited by 130
Kobayashi, M., Oshima, S., Maeyashiki, C., Nibe, Y., Otsubo, K., Matsuzawa, Y., Nemoto, Y., Nagaishi, T., Okamoto, R., Tsuchiya, K., et al. (2016) · Scientific Reports · doi:10.1038/srep36780 · Cited by 124
“Next, to understand the mechanism underlying this, we consider that cyclin D promotes cell cycle as a main regulator 34 .”
EGF Receptor–Dependent YAP Activation Is Important for Renal Recovery from AKI
Chen, J., You, H., Li, Y., Xu, Y., He, Q., & Harris, R. C. (2018) · Journal of the American Society of Nephrology · doi:10.1681/asn.2017121272 · Cited by 120
Anti-tumor activity of non-steroidal anti-inflammatory drugs: Cyclooxygenase-independent targets
Liggett, J. L., Zhang, X., Eling, T. E., & Baek, S. J. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.01.021 · Cited by 124
“There is a substantial body of experimental evidence showing that cyclin D1 could be a potential cancer therapeutic target [83].”
BackgroundMicroRNA and Protein Profiling of Brain Metastasis Competent Cell-Derived Exosomes
Camacho, L., Guerrero, P., & Marchetti, D. (2013) · PLoS ONE · doi:10.1371/journal.pone.0073790 · Cited by 121
“Its over-expression has been linked to the development and progression of breast cancer and melanomas among others [46,47].”
BackgroundCai, J., Wu, J., Zhang, H., Fang, L., Huang, Y., Yang, Y., Zhu, X., Li, R., & Li, M. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2651 · Cited by 125
“and protein in a variety of tumors including NSCLC, breast cancer, melanoma, and pancreatic cancer (30).”
Hace1 controls ROS generation of vertebrate Rac1-dependent NADPH oxidase complexes
Daugaard, M., Nitsch, R., Razaghi, B., McDonald, L., Jarrar, A., Torrino, S., Castillo-Lluva, S., Rotblat, B., Li, L., Malliri, A., et al. (2013) · Nature Communications · doi:10.1038/ncomms3180 · Cited by 114
Yang, L., Yang, Y., Zhang, J., Li, M., Yang, L., Wang, X., Chen, M., Zhang, H., He, B., Wang, X., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01983-1 · Cited by 136
“24 Cyclin-dependent kinase 4 and 6 (CDK4/6) play an important role in the transition from G1 to S phase.”
BackgroundHsa-miR-326 targets CCND1 and inhibits non-small cell lung cancer development
Sun, C., Huang, C., Li, S., Yang, C., Xi, Y., Wang, L., Zhang, F., Fu, Y., & Li, D. (2016) · Oncotarget · doi:10.18632/oncotarget.7071 · Cited by 124
“…negatively expressed related to miR-326 cyclin D1 is important oncogene that shown strong power of oncogenicity, by promotion of cell growth, migration, invasion and epithelial mesenchymal transition (EMT), as well as inhibition of cell apoptosis in many tumors including lung cancer [35, 41, 42].”
Cell Cycle–Targeted Cancer Therapies
Sherr, C. J., & Bártek, J. (2016) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-040716-075628 · Cited by 129
“…with CDKs 4 and 6, and their stability and nuclear import are all mitogen-dependent events, mitogen withdrawal results in rapid turnover of cyclin D, loss of CDK4 and CDK6 activity, and arrest during G1/G0 (Alt et al. 2000, Choi & Anders 2014, Musgrove et al. 2011, Sherr 1995, Vaites et al. 2011).”
BackgroundDu, W., Wang, S., Zhou, Q., Li, X., Chu, J., Chang, Z., Tao, Q., Ng, E. K. O., Fang, J., Sung, J. J. �., et al. (2012) · Oncogene · doi:10.1038/onc.2012.359 · Cited by 129
From MGUS to Multiple Myeloma, a Paradigm for Clonal Evolution of Premalignant Cells
van Nieuwenhuijzen, N., Spaan, I., Raymakers, R. A. P., & Peperzak, V. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3115 · Cited by 129
“It is high in patientswith t(4;14), t(14;16), and t(14;20),”
BackgroundInfluentialDai, Y., Qiu, Z., Diao, Z., Shen, L., Xue, P., Sun, H., & Hu, Y. (2012) · Placenta · doi:10.1016/j.placenta.2012.07.012 · Cited by 123
“Highly expressed cyclin D1 has been described in various cancers, suggesting that it may provide cells with a distinct growth advantage [11].”
BackgroundATARiS: Computational quantification of gene suppression phenotypes from multisample RNAi screens
Shao, D. D., Tsherniak, A., Gopal, S., Weir, B. A., Tamayo, P., Stransky, N., Schumacher, S. E., Zack, T. I., Beroukhim, R., Garraway, L. A., et al. (2013) · Genome Research · doi:10.1101/gr.143586.112 · Cited by 118
“The genes whose solutions most significantly correlated to CCND1 solution included a gene that encodes the CCND1-binding partner CDK6 (no solution was available for the other cyclin D–binding partner CDK4) and also members of the mitogenic pathway, including KRAS and RAF1 (Fig.”
BackgroundZhang, Y.-X., Sicinska, E., Czaplinski, J. T., Remillard, S. P., Moss, S., Wang, Y., Brain, C., Loo, A., Snyder, E. L., Demetri, G. D., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0387 · Cited by 114
“org Mol Cancer Ther; 13(9) September 2014 2189”
BackgroundInfluentialK63-Linked Ubiquitination in Kinase Activation and Cancer
Wang, G., Gao, Y., Li, L., Jin, G., Cai, Z., Chao, J. I., & Lin, H.-K. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00005 · Cited by 124
“Furthermore, many transcription factors have been demonstrated to be overexpressed and play potent oncogenic functions in tumorigenesis, such as Myc (Pelengaris et al., 2002), CyclinD1 (Musgrove et al., 2011) and inhibitors of DNA binding (ID; Hasskarl and Munger, 2002).”
BackgroundFahrioğlu, U., Dodurga, Y., Elmas, L., & Seçme, M. (2015) · Gene · doi:10.1016/j.gene.2015.10.061 · Cited by 113
Metadata
- Authors
- Musgrove, E. A., Caldon, C. E., Barraclough, J., Stone, A., & Sutherland, R. L.
- Affiliations
- Garvan Institute of Medical Research (AU)
- Corresponding author
- Sutherland, Robert L.
- ORCID
- Caldon, C. Elizabeth
- Venue
- Nature Reviews Cancer
- Published
- 2011-07-07
- Volume
- 11
- Issue
- 8
- Pages
- 558-572
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2089655089
- Cited by
- 1,370
- References
- 190
- Citations by year
- 2026: 54 · 2025: 65 · 2024: 57 · 2023: 78 · 2022: 85 · 2021: 102 · 2020: 113 · 2019: 100 · 2018: 93 · 2017: 130 · 2016: 129 · 2015: 105 · 2014: 92 · 2013: 91 · 2012: 75
- FWCI
- 7.64
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Keywords
- cyclin D1, cyclin D, cyclin-dependent kinases, CDK4, CDK6, oncogene deregulation, cancer therapy, therapeutic target, biomarkers, patient subgroup identification, tumor progression
- MeSH terms
- Humans, Neoplasms, Oncogenes, Polymorphism, Genetic, Cyclin D
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.